Quinidine is an antimalarial schizonticide and an antiarrhythmic agent with Class la activity; it is the d-isomer of quinine, and its molecular weight is 324.43. Quinidine sulfate is the sulfate salt of quinidine; its chemical name is cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate(2:1) dihydrate.

its empirical formula is (C ₂₀ H ₂₄ N ₂ O ₂ ) ₂ · H ₂ SO ₄ ·2H ₂ O; and its molecular weight is 782.95, of which 82.9% is quinidine base.

Each Quinidex Extentabs® tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are acacia, acetylated monoglycerides, calcium sulfate, carnauba wax, edible ink, FD&C Blue 2, gelatin, guar gum, magnesium oxide, magnesium stearate, polysorbates, shellac, sucrose, titanium dioxide, white wax, and other ingredients, one of which is a corn derivative. Tablets may also contain FD&C Red 40 and FD&C Yellow 6 Aluminum Lakes. These tablets comply with USP Drug Release Test 1.

Last updated on RxList: 12/8/2004

Conversion of Atrial Fibrillation/Flutter

In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, Quinidex is indicated as a means of restoring normal sinus rhythm. If this use of Quinidex does not restore sinus rhythm within a reasonable time (see DOSAGE AND ADMINISTRATION), then Quinidex should be discontinued.

Reduction of Frequency of Relapse into Atrial Fibrillation/Flutter

Chronic therapy with Quinidex is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter; generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with Quinidex. The increased risk of death should specifically be considered. Quinidex should be used only after alternative measures (e.g., use of other drugs to control ventricular rate) have been found to be inadequate.

In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure.

Suppression of Ventricular Arrhythmias

Quinidex is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring with exercise.

Antiarrhythmic drugs (including Quinidex) have not been shown to enhance survival in patients with ventricular arrhythmias.

Conversion of Atrial Fibrillation/Flutter to Sinus Rhythm

Especially in patients with known structural heart disease or other risk factors for toxicity, initiation or dose-adjustment of treatment with Quinidex should generally be performed in a setting where facilities and personnel for monitoring and resuscitation are continuously available.

Patients with symptomatic atrial fibrillation/flutter should be treated with Quinidex only after ventricular rate control (e.g., with digitalis or (beta)-blockers) has failed to provide satisfactory control of symptoms. Adequate trials have not identified an optimal regimen of Quinidex for conversion of atrial fibrillation/flutter to sinus rhythm. Therapy with Quinidex should begin with one tablet (300 mg; 249 mg of quinidine base) every 8 to 12 hours. If this regimen is well tolerated, if the serum quinidine level is still well within the laboratory's therapeutic range, and if this regimen has not resulted in conversion, then the dose may be cautiously raised. If, at any point during administration, the QRS complex widens to 130% of its pre-treatment duration; the QT _c interval widens to 130% of its pre-treatment duration and is then longer than 500 ms; P waves disappear; or the patient develops significant tachycardia, symptomatic bradycardia, or hypotension, then Quinidex is discontinued, and other means of conversion (e.g., direct-current cardioversion) are considered.

Reduction of Frequency of Relapse into Atrial Fibrillation/Flutter

In a patient with a history of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy with Quinidex should be an increase in the average time between episodes. In most patients, the tachyarrhythmia will recur during therapy with Quinidex, and a single recurrence should not be interpreted as therapeutic failure.

Especially in patients with known structural heart disease or other risk factors for toxicity, initiation or dose-adjustment of treatment with Quinidex should generally be performed in a setting where facilities and personnel for monitoring and resuscitation are continously available.

Monitoring should be continued for two or three days after initiation of the regimen on which the patient will be discharged.

Therapy with Quinidex should begin with one tablet (300 mg; 249 mg of quinidine base) every eight to twelve hours. If this regimen is well tolerated, if the serum quinidine level is still well within the laboratory's therapeutic range, and if the average time between arrhythmic episodes has not been satisfactorily increased, then the dose may be cautiously raised. The total daily dosage should be reduced if the QRS complex widens to 130% of its pre-treatment duration; the QT _c interval widens to 130% of its pre-treatment duration and is then longer than 500 ms; P waves disappear; or the patient develops significant tachycardia, symptomatic bradycardia, or hypotension.

Suppression of Ventricular Arrhythmias

Dosing regimens for the use of quinidine sulfate in suppressing life-threatening ventricular arrhythmias have not been adequately studied.

Described regimens have generally been similar to the regimen described just above for the prophylaxis of symptomatic atrial fibrillation/flutter. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring with exercise.

Quinidex Extentabs® Tablets (quinidine sulfate extended-release tablets, USP) are 300 mg, white, sugar-coated, round tablets marked with "QUINIDEX" and "AHR". The tablets are available in bottles and in DIS-CO® unit-dose packages as follows:

bottle of 100                       NDC 0031-6649-63

bottle of 250                       NDC 0031-6649-67

unit-dose pack of 100         NDC 0031-6649-64

Store at controlled room temperature, 20°-25°C (68°-77°F). Dispense in well-closed, light-resistant container.

Caution:   Federal law prohibits dispensing without prescription.

Manufactured by:
Pharmaceutical Division
A.H. Robins Company
Richmond, VA 23220

Last updated on RxList: 12/8/2004

Quinidine preparations have been used for many years, but there are only sparse data from which to estimate the incidence of various adverse reactions. The adverse reactions most frequently reported have consistently been gastrointestinal, including diarrhea, nausea, vomiting, and heartburn/esophagitis. In one study of 245 adult outpatients who received quinidine to suppress premature ventricular contractions, the incidences of reported adverse experiences were as shown in the table below. The most serious quinidine-associated adverse reactions are described above under WARNINGS.

Vomiting and diarrhea can occur as isolated reactions to therapeutic levels of quinidine, but they also may be the first signs of cinchonism , a syndrome that also may include tinnitus, reversible high-frequency hearing loss, deafness, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium. Cinchonism is most often a sign of chronic quinidine toxicity, but it may appear in sensitive patients after a single moderate dose.

A few cases of hepatotoxicity , including granulomatous hepatitis, have been reported in patients receiving quinidine. All of these have appeared during the first few weeks of therapy, and most (not all) have remitted once quinidine was withdrawn.

Autoimmune and inflammatory syndromes associated with quinidine therapy have included pneumonitis, fever, urticaria, flushing, exfoliative rash, bronchospasm, psoriasiform rash, pruritus and lymphadenopathy, hemolytic anemia, vasculitis, thrombocytopenic purpura, uveitis, angioedema, agranulocytosis, the sicca syndrome, arthralgia, myalgia, elevation in serum levels of skeletal-muscle enzymes, and a disorder resembling systemic lupus erythematosus.

Convulsions, apprehension, and ataxia have been reported, but it is not clear that these were not simply the results of hypotension and consequent cerebral hypoperfusion. There are many reports of syncope. Acute psychotic reactions have been reported to follow the first dose of quinidine, but these reactions appear to be extremely rare.

Other adverse reactions occasionally reported include depression, mydriasis, disturbed color perception, night blindness, scotomata, optic neuritis, visual field loss, photosensitivity, and abnormalities of pigmentation.

Altered pharmacokinetics of quinidine:   Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine.

By pharmacokinetic mechanisms that are not well understood, quinidine levels are increased by coadministration of amiodarone or cimetidine. Very rarely, and again by mechanisms not understood, quinidine levels are decreased by coadministration of nifedipine.

Hepatic elimination of quinidine may be accelerated by coadministration of drugs ( phenobarbital, phenytoin, rifampin ) that induce production of cytochrome P ₄₅₀ IIIA ₄ .

Perhaps because of competition for the P ₄₅₀ IIIA ₄ metabolic pathway, quinidine levels rise when ketoconazole is coadministered.

Coadministration of propranolol usually does not affect quinidine pharmacokinetics, but in some studies the (beta)-blocker appeared to cause increases in the peak serum levels of quinidine, decreases in quinidine's volume of distribution, and decreases in total quinidine clearance. The effects (if any) of coadministration of other (beta)-blockers on quinidine pharmacokinetics have not been adequately studied.

Diltiazem significantly decreases the clearance and increases the t _½ of quinidine, but quinidine does not alter the kinetics of diltiazem.

Hepatic clearance of quinidine is significantly reduced during coadministration of verapamil , with corresponding increases in serum levels and half-life.

Altered pharmacokinetics of other drugs:   Quinidine slows the elimination of digoxin and simultaneously reduces digoxin's apparent volume of distribution. As a result, serum digoxin levels may be as much as doubled. When quinidine and digoxin are coadministered, digoxin doses usually need to be reduced. Serum levels of digitoxin are also raised when quinidine is coadministered, although the effect appears to be smaller.

By a mechanism that is not understood, quinidine potentiates the anticoagulatory action of warfarin , and the anticoagulant dosage may need to be reduced.

Cytochrome P ₄₅₀ IID ₆ is an enzyme critical to the metabolism of many drugs, notably including mexiletine , some phenothiazines , and most polycyclic antidepressants . Constitutional deficiency of cytochrome P ₄₅₀ IID ₆ is found in less than 1% of Orientals, in about 2% of American blacks, and in about 8% of American whites. Testing with debrisoquine is sometimes used to distinguish the P ₄₅₀ IID ₆ -deficient "poor metabolizers" from the majority-phenotype "extensive metabolizers."

When drugs whose metabolism is P ₄₅₀ IID ₆ -dependent are given to poor metabolizers, the serum levels achieved are higher, sometimes much higher, than the serum levels achieved when identical doses are given to extensive metabolizers. To obtain similar clinical benefit without toxicity, doses given to poor metabolizers may need to be greatly reduced. In the cases of prodrugs whose actions are actually mediated by P ₄₅₀ IID ₆ -produced metabolites (for example, codeine and hydrocodone , whose analgesic and antitussive effects appear to be mediated by morphine and hydromorphone, respectively), it may not be possible to achieve the desired clinical benefits in poor metabolizers.

Quinidine is not metabolized by cytochrome P ₄₅₀ IID ₆ , but therapeutic serum levels of quinidine inhibit the action of cytochrome P ₄₅₀ IID ₆ , effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P ₄₅₀ IID ₆ .

Perhaps by competing for pathways of renal clearance, coadministration of quinidine causes an increase in serum levels of procainamide.

Serum levels of haloperidol are increased when quinidine is coadministered.

Presumably because both drugs are metabolized by cytochrome P ₄₅₀ IIIA ₄ , coadministration of quinidine causes variable slowing of the metabolism of nifedipine . Interactions with other dihydropyridine calcium-channel blockers have not been reported, but these agents (including felodipine, nicardipine, and nimodipine ) are all dependent upon P ₄₅₀ IIIA ₄ for metabolism, so similar interactions with quinidine should be anticipated.

Altered pharmacodynamics of other drugs:   Quinidine's anticholinergic, vasodilating, and negative inotropic actions may be additive to those of other drugs with these effects, and antagonistic to those of drugs with cholinergic, vasoconstricting, and positive inotropic effects. For example, when quinidine and verapamil are coadministered in doses that are each well tolerated as monotherapy, hypotension attributable to additive peripheral (alpha)-blockade is sometimes reported.

Quinidine potentiates the actions of depolarizing (succinylcholine, decamethonium) and nondepolarizing (d-tubocurarine, pancuronium) neuromuscular blocking agents . These phenomena are not well understood, but they are observed in animals models as well as in humans. In addition, in vitro addition of quinidine to the serum of pregnant women reduces the activity of pseudocholinesterase, an enzyme that is essential to the metabolism of succinylcholine.

Non-interactions of quinidine with other drugs:   Quinidine has no clinically significant effect on the pharmacokinetics of diltiazem, flecainide, mephenytoin, metoprolol, propafenone, propranolol, quinine, timolol, or tocainide.

Conversely, the pharmacokinetics of quinidine are not significantly affected by caffeine, ciprofloxacin, digoxin, diltiazem, felodipine, omeprazole, or quinine . Quinidine's pharmacokinetics are also unaffected by cigarette smoking.

Last updated on RxList: 12/8/2004

Mortality

Proarrhythmic Effects

Like many other drugs (including all other Class la antiarrhythmics), quinidine prolongs the QT _c interval, and this can lead to torsades de pointes , a life-threatening ventricular arrhythmia (see OVERDOSAGE). The risk of torsades is increased by bradycardia, hypokalemia, hypomagnesemia, or high serum levels of quinidine, but it may appear in the absence of any of these risk factors. The best predictor of this arrhythmia appears to be the length of the QT _c interval, and quinidine should be used with extreme care in patients who have preexisting long-QT syndromes, who have histories of torsades de pointes of any cause, or who have previously responded to quinidine (or other drugs that prolong ventricular repolarization) with marked lengthening of the QT _c interval. Estimation of the incidence of torsades in patients with therapeutic levels of quinidine is not possible from the available data.

Other ventricular arrhythmias that have been reported with quinidine include frequent extrasystoles, ventricular tachycardia, ventricular flutter, and ventricular fibrillation.

Paradoxical Increase in Ventricular Rate in Atrial Flutter/Fibrillation

When quinidine is administered to patients with atrial flutter/fibrillation the desired pharmacologic reversion to sinus rhythm may (rarely) be preceded by a showing of the atrial rate with a consequent increase in the rate of beats conducted to the ventricles. The resulting ventricular rate may be very high (greater than 200 beats per minute) and poorly tolerated. This hazard may be decreased if partial atrioventricular block is achieved prior to initiation of quinidine therapy, using conduction-reducing drugs such as digitalis, verapamil, diltiazem, or a (beta)-receptor blocking agent.

Exacerbated Bradycardia in Sick Sinus Syndrome

In patients with the sick sinus syndrome, quinidine has been associated with marked sinus node depression and bradycardia.

Pharmacokinetic Considerations

Renal or hepatic dysfunction causes the elimination of quinidine to be slowed, while congestive heart failure causes a reduction in quinidine's apparent volume of distribution. Any of these conditions can lead to quinidine toxicity if dosage is not appropriately reduced. In addition, interactions with coadministered drugs can alter the serum concentration and activity of quinidine, leading either to toxicity or to lack of efficacy if the dose of quinidine is not appropriately modified. (See PRECAUTIONS Drug Interactions .)

Vagolysis

Because quinidine opposes the atrial and A-V nodal effects of vagal stimulation, physical or pharmacological vagal maneuvers undertaken to terminate paroxysmal supraventricular tachycardia may be ineffective in patients receiving quinidine.

General

All the precautions applying to regular quinidine therapy apply to this product. Hypersensitivity or anaphylactoid reactions to quinidine, although rare, should be considered, especially during the first weeks of therapy. Hospitalization for close clinical observation, electrocardiographic monitoring, and determination of serum quinidine levels are indicated when large doses of quinidine are used or with patients who present an increased risk.

Laboratory Tests

Periodic blood counts and liver and kidney function tests should be performed during long-term therapy; the drug should be discontinued if blood dyscrasias or evidence of hepatic or renal dysfunction occurs.

Heart Block

In patients without implanted pacemakers who are at high risk of complete atrioventricular block (e.g., those with digitalis intoxication, second-degree atrioventricular block, or severe intraventricular conduction defects), quinidine should be used only with caution.

Drug Interactions

Altered pharmacokinetics of quinidine:   Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine.

By pharmacokinetic mechanisms that are not well understood, quinidine levels are increased by coadministration of amiodarone or cimetidine. Very rarely, and again by mechanisms not understood, quinidine levels are decreased by coadministration of nifedipine.

Hepatic elimination of quinidine may be accelerated by coadministration of drugs ( phenobarbital, phenytoin, rifampin ) that induce production of cytochrome P ₄₅₀ IIIA ₄ .

Perhaps because of competition for the P ₄₅₀ IIIA ₄ metabolic pathway, quinidine levels rise when ketoconazole is coadministered.

Coadministration of propranolol usually does not affect quinidine pharmacokinetics, but in some studies the (beta)-blocker appeared to cause increases in the peak serum levels of quinidine, decreases in quinidine's volume of distribution, and decreases in total quinidine clearance. The effects (if any) of coadministration of other (beta)-blockers on quinidine pharmacokinetics have not been adequately studied.

Diltiazem significantly decreases the clearance and increases the t _½ of quinidine, but quinidine does not alter the kinetics of diltiazem.

Hepatic clearance of quinidine is significantly reduced during coadministration of verapamil , with corresponding increases in serum levels and half-life.

Altered pharmacokinetics of other drugs:   Quinidine slows the elimination of digoxin and simultaneously reduces digoxin's apparent volume of distribution. As a result, serum digoxin levels may be as much as doubled. When quinidine and digoxin are coadministered, digoxin doses usually need to be reduced. Serum levels of digitoxin are also raised when quinidine is coadministered, although the effect appears to be smaller.

By a mechanism that is not understood, quinidine potentiates the anticoagulatory action of warfarin , and the anticoagulant dosage may need to be reduced.

Cytochrome P ₄₅₀ IID ₆ is an enzyme critical to the metabolism of many drugs, notably including mexiletine , some phenothiazines , and most polycyclic antidepressants . Constitutional deficiency of cytochrome P ₄₅₀ IID ₆ is found in less than 1% of Orientals, in about 2% of American blacks, and in about 8% of American whites. Testing with debrisoquine is sometimes used to distinguish the P ₄₅₀ IID ₆ -deficient "poor metabolizers" from the majority-phenotype "extensive metabolizers."

When drugs whose metabolism is P ₄₅₀ IID ₆ -dependent are given to poor metabolizers, the serum levels achieved are higher, sometimes much higher, than the serum levels achieved when identical doses are given to extensive metabolizers. To obtain similar clinical benefit without toxicity, doses given to poor metabolizers may need to be greatly reduced. In the cases of prodrugs whose actions are actually mediated by P ₄₅₀ IID ₆ -produced metabolites (for example, codeine and hydrocodone , whose analgesic and antitussive effects appear to be mediated by morphine and hydromorphone, respectively), it may not be possible to achieve the desired clinical benefits in poor metabolizers.

Quinidine is not metabolized by cytochrome P ₄₅₀ IID ₆ , but therapeutic serum levels of quinidine inhibit the action of cytochrome P ₄₅₀ IID ₆ , effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P ₄₅₀ IID ₆ .

Perhaps by competing for pathways of renal clearance, coadministration of quinidine causes an increase in serum levels of procainamide.

Serum levels of haloperidol are increased when quinidine is coadministered.

Presumably because both drugs are metabolized by cytochrome P ₄₅₀ IIIA ₄ , coadministration of quinidine causes variable slowing of the metabolism of nifedipine . Interactions with other dihydropyridine calcium-channel blockers have not been reported, but these agents (including felodipine, nicardipine, and nimodipine ) are all dependent upon P ₄₅₀ IIIA ₄ for metabolism, so similar interactions with quinidine should be anticipated.

Altered pharmacodynamics of other drugs:   Quinidine's anticholinergic, vasodilating, and negative inotropic actions may be additive to those of other drugs with these effects, and antagonistic to those of drugs with cholinergic, vasoconstricting, and positive inotropic effects. For example, when quinidine and verapamil are coadministered in doses that are each well tolerated as monotherapy, hypotension attributable to additive peripheral (alpha)-blockade is sometimes reported.

Quinidine potentiates the actions of depolarizing (succinylcholine, decamethonium) and nondepolarizing (d-tubocurarine, pancuronium) neuromuscular blocking agents . These phenomena are not well understood, but they are observed in animals models as well as in humans. In addition, in vitro addition of quinidine to the serum of pregnant women reduces the activity of pseudocholinesterase, an enzyme that is essential to the metabolism of succinylcholine.

Non-interactions of quinidine with other drugs:   Quinidine has no clinically significant effect on the pharmacokinetics of diltiazem, flecainide, mephenytoin, metoprolol, propafenone, propranolol, quinine, timolol, or tocainide.

Conversely, the pharmacokinetics of quinidine are not significantly affected by caffeine, ciprofloxacin, digoxin, diltiazem, felodipine, omeprazole, or quinine . Quinidine's pharmacokinetics are also unaffected by cigarette smoking.

Information for Patients

Before prescribing Quinidex Extentabs® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected (see CLINICAL PHARMACOLOGY).

Discussion should include the facts

• that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
• that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
• that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
• that such data as are available suggest that treatment with Quinidex is likely to increase the patient's risk of death.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Animal studies to evaluate quinidine's carcinogenic or mutagenic potential have not been performed. Similarly, there are no animal data as to quinidine's potential to impair fertility.

Pregnancy

Pregnancy Category C:   Animal reproductive studies have not been conducted with quinidine. There are no adequate and well-controlled studies in pregnant women. Quinidine should be given to a pregnant woman only if clearly needed.

In one neonate whose mother had received quinidine throughout her pregnancy, the serum level of quinidine was equal to that of the mother, with no apparent ill effect. The level of quinidine in amniotic fluid was about three times higher than that found in serum.

Labor and Delivery

Quinine is said to be oxytocic in humans, but there are no adequate data as to quinidine's effects (if any) on human labor and delivery.

Nursing Mothers

Quinidine is present in human milk at levels slightly lower than those in maternal serum; a human infant ingesting such milk should (scaling directly by weight) be expected to develop serum quinidine levels at least an order of magnitude lower than those of the mother. On the other hand, the pharmacokinetics and pharmacodynamics of quinidine in human infants have not been adequately studied, and neonates' reduced protein binding of quinidine may increase their risk of toxicity at low total serum levels. Administration of quinidine should (if possible) be avoided in lactating women who continue to nurse.

Geriatric Use

Safety and efficacy of quinidine in elderly patients have not been systematically studied.

Pediatric Use

In antimalarial trials, quinidine was as safe and effective in pediatric patients as in adults. Notwithstanding the known pharmacokinetic differences between the pediatric population and adults (see CLINICAL PHARMACOLOGY Pharmacokinetics ), pediatric patients in these trials received the same doses (on a mg/kg basis) as adults.

Safety and effectiveness of the antiarrhythmic use of quinidine in pediatric patients have not been established in well-controlled clinical trials.

Last updated on RxList: 12/8/2004

Overdoses with various oral formulations of quinidine have been well described. Death has been described after a 5-gram ingestion by a toddler, while an adolescent was reported to survive after ingesting 8 grams of quinidine.

The most important ill effects of acute quinidine overdoses are ventricular arrhythmias and hypotension. Other signs and symptoms of overdose may include vomiting, diarrhea, tinnitus, high-frequency hearing loss, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium.

Arrhythmias

Serum quinidine levels can be conveniently assayed and monitored, but the electrocardiographic QT _c interval is a better predictor of quinidine-induced ventricular arrhythmias.

The necessary treatment of hemodynamically unstable polymorphic ventricular tachycardia (including torsades de pointes ) is withdrawal of treatment with quinidine and either immediate cardioversion or, if a cardiac pacemaker is in place or immediately available, immediate overdrive pacing. After pacing or cardioversion, further management must be guided by the length of the QT _c interval.

Quinidine-associated ventricular tachyarrhythmias with normal underlying QT _c intervals have not been adequately studied. Because of the theoretical possibility of QT-prolonging effects that might be additive to those of quinidine, other antiarrhythmics with Class I (disopyramide, procainamide) or Class III activities should (if possible) be avoided. Similarly, although the use of bretylium in quinidine overdose has not been reported, it is reasonable to expect that the (alpha)-blocking properties of bretylium might be additive to those of quinidine, resulting in problematic hypotension.

If the post-cardioversion QT _c interval is prolonged, then the pre-cardioversion polymorphic ventricular tachyarrhythmia was (by definition) torsades de pointes . In this case, lidocaine and bretylium are unlikely to be of value, and other Class I antiarrhythmics (disopyramide, procainamide) are likely to exacerbate the situation. Factors contributing to QT _c prolongation (especially hypokalemia and hypomagnesemia) should be sought out and (if possible) aggressively corrected. Prevention of recurrent torsades may require sustained overdrive pacing or the cautious administration of isoproterenol (30 to 150 ng/kg/min).

Hypotension

Quinidine-induced hypotension that is not due to an arrhythmia is likely to be a consequence of quinidine-related (alpha)-blockade and vasorelaxation. Simple repletion of central volume (Trendelenburg positioning, saline infusion) may be sufficient therapy; other interventions reported to have been beneficial in this setting are those that increase peripheral vascular resistance, including (alpha)-agonist catecholamines (norepinephrine, metaraminol) and the Military Anti-Shock Trousers.

Treatment

Adequate studies of orally-administered activated charcoal in human overdoses of quinidine have not been reported, but there are animal data showing significant enhancement of systemic elimination following this intervention, and there is at least one human case report in which the elimination half-life of quinidine in the serum was apparently shortened by repeated gastric lavage. Activated charcoal should be avoided if an ileus is present; the conventional dose is 1 gram/kg, administered every 2 to 6 hours as a slurry with 8 mL/kg of tap water. Although renal elimination of quinidine might theoretically be accelerated by maneuvers to acidify the urine, such maneuvers are potentially hazardous and of no demonstrated benefit.

Quinidine is not usefully removed from the circulation by dialysis. Following quinidine overdose, drugs that delay elimination of quinidine (cimetidine, carbonic-anhydrase inhibitors, thiazide diuretics) should be withdrawn unless absolutely required.

In managing overdose, consider the possibilities of multiple-drug overdoses, drug-drug interactions, and unusual drug kinetics in your patient.

Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine.

In the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block.

Quinidine is also contraindicated in patients who, like those will myasthenia gravis, might be adversely affected by an anticholinergic agent.

Last updated on RxList: 12/8/2004

Pharmacokinetics

The absolute bioavailability of quinidine from Quinidex is about 70%, but this varies widely (45-100%) between patients. The less-than-complete bioavailability is the result of first-pass metabolism in the liver. Peak serum levels generally appear about 6 hours after dosing.

Although the effect of food upon Quinidex absorption has not been studied, peak serum quinidine levels obtained from immediate-release quinidine sulfate are known to be delayed by nearly an hour (without change in total absorption) when these products are taken with food.

The volume of distribution of quinidine is 2 to 3 L/kg in healthy young adults, but this may be reduced to as little as 0.5 L/kg in patients with congestive heart failure, or increased to 3 to 5 L/kg in patients with cirrhosis of the liver. At concentrations of 2 to 5 mg/L (6.5 to 16.2 µmol/L), the fraction of quinidine bound to plasma proteins (mainly to (alpha) ₁ -acid glycoprotein and to albumin) is 80 to 88% in adults and older children, but it is lower in pregnant women, and in infants and neonates it may be as low as 50 to 70%. Because (alpha) ₁ -acid glycoprotein levels are increased in response to stress, serum levels of total quinidine may be greatly increased in settings such as acute myocardial infarction, even though the serum content of unbound (active) drug may remain normal. Protein binding is also increased in chronic renal failure, but binding abruptly descends toward or below normal when heparin is administered for hemodialysis.

Quinidine clearance typically proceeds at 3 to 5 mL/min/kg in adults, but clearance in children may be twice or three times as rapid. The elimination half-life is 6 to 8 hours in adults and 3 to 4 hours in children. Quinidine clearance is unaffected by hepatic cirrhosis, so the increased volume of distribution seen in cirrhosis leads to a proportionate increase in the elimination half-life.

Most quinidine is eliminated hepatically via the action of cytochrome P ₄₅₀ IIIA ₄ ; there are several different hydroxylated metabolites, and some of these have antiarrhythmic activity.

The most important of quinidine's metabolites is 3-hydroxy-quinidine (3HQ), serum levels of which can approach those of quinidine in patients receiving conventional doses of Quinidex. The volume of distribution of 3HQ appears to be larger than that of quinidine, and the elimination half-life of 3HQ is about 12 hours.

As measured by antiarrhythmic effects in animals, by QT _c prolongation in human volunteers, or by various in vitro techniques, 3HQ has at least half the antiarrhythmic activity of the parent compound, so it may be responsible for a substantial fraction of the effect of Quinidex in chronic use.

When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline. Renal clearance involves both glomerular filtration and active tubular secretion, moderated by (pH-dependent) tubular reabsorption. The new renal clearance is about 1 mL/min/kg in healthy adults.

When renal function is taken into account, quinidine clearance is apparently independent of patient age.

Assays of serum quinidine levels are widely available, but the results of modern assays may not be consistent with results cited in the older medical literature. The serum levels of quinidine cited in this package insert are those derived from specific assays, using either benzene extraction or (preferably) reverse-phase high-pressure liquid chromatography. In matched samples, older assays might unpredictably have given results that were as much as two or three times higher. A typical "therapeutic" concentration range is 2 to 6 mg/L (6.2 to 18.5 µmol/L).

Mechanisms of Action

In patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, with little effect upon sporozites or upon pre-erythrocytic parasites. Quinidine is gametocidal to Plasmodium vivax and P. malariae, but not to P. falciparum.

In cardiac muscle and in Purkinje fibers, quinidine depresses the rapid inward depolarizing sodium current, thereby slowing phase-0 depolarization and reducing the amplitude of the action potential without affecting the resting potential. In normal Purkinje fibers, it reduces the slope of phase-4 depolarization, shifting the threshold voltage upward toward zero. The result is slowed conduction and reduced automaticity in all parts of the heart, with increase of the effective refractory period relative to the duration of the action potential in the atria, ventricles, and Purkinje tissues. Quinidine also raises the fibrillation thresholds of the atria and ventricles, and it raises the ventricular de fibrillation threshold as well. Quinidine's actions fall into Class Ia in the Vaughan-Williams classification.

By slowing conduction and prolonging the effective refractory period, quinidine can interrupt or prevent reentrant arrhythmias and arrhythmias due to increased automaticity, including atrial flutter, atrial fibrillation, and paroxysmal supraventricular tachycardia.

In patients with the sick sinus syndrome, quinidine can cause marked sinus node depression and bradycardia. In most patients, however, use of quinidine is associated with an increase in the sinus rate.

Quinidine prolongs the QT interval in a dose-related fashion. This may lead to increased ventricular automaticity and polymorphic ventricular tachycardias, including torsades de pointes (see WARNINGS).

In addition, quinidine has anticholinergic activity, it has negative inotropic activity, and it acts peripherally as an (alpha)-adrenergic antagonist (that is, as a vasodilator).

Clinical Effects

Maintenance of sinus rhythm after conversion from atrial fibrillation:   In six clinical trials (published between 1970 and 1984) with a total of 808 patients, quinidine (418 patients) was compared to nontreatment (258 patients) or placebo (132 patients) for the maintenance of sinus rhythm after cardioversion from chronic atrial fibrillation. Quinidine was consistently more efficacious in maintaining sinus rhythm, but a meta-analysis found that mortality in the quinidine-exposed patients (2.9%) was significantly greater than mortality in the patients who had not been treated with active drug (0.8%). Suppression of atrial fibrillation with quinidine has theoretical patient benefits (e.g., improved exercise tolerance; reduction in hospitalization for cadioversion; lack of arrhythmia-related palpitations, dyspnea, and chest pain; reduced incidence of systemic embolism and/or stroke), but these benefits have never been demonstrated in clinical trials. Some of these benefits (e.g., reduction in stroke incidence) may be achievable by other means (anticoagulation).

By slowing the rate of atrial flutter/fibrillation, quinidine can decrease the degree of atrioventricular block and cause an increase, sometimes marked, in the rate at which supraventricular impulses are successfully conducted by the atrioventricular node, with a resultant paradoxical increase in ventricular rate (see WARNINGS).

Non-life-threatening ventricular arrhythmias:   In studies of patients with a variety of ventricular arrhythmias (mainly frequent ventricular premature beats and non-sustained ventricular tachycardia), quinidine (total N=502) has been compared to flecainide (N=141), mexiletine (N=246), propafenone (N=53), and tocainide (N=67). In each of these studies, the mortality in the quinidine group was numerically greater than the mortality in the comparator group. When the studies were combined in a meta-analysis, quinidine was associated with a statistically significant threefold relative risk of death.

At therapeutic doses, quinidine's only consistent effect upon the surface electrocardiogram is an increase in the QT interval. This prolongation can be monitored as a guide to safety, and it may provide better guidance than serum drug levels (see WARNINGS).

Last updated on RxList: 12/8/2004

Before prescribing Quinidex Extentabs® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected (see CLINICAL PHARMACOLOGY).

Discussion should include the facts

• that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
• that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
• that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
• that such data as are available suggest that treatment with Quinidex is likely to increase the patient's risk of death.

Last updated on RxList: 12/8/2004

IMPORTANT NOTE: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your health care professional. Always seek the advice of your health care professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your health care professional. This information does not contain any assurances that this product is safe, effective, or appropriate for you.

QUINIDINE - ORAL

(KWIN-ih-deen)

COMMON BRAND NAME(S): Quinidex

WARNING: Before taking this drug for treatment of an irregular heartbeat, you should discuss your risks and benefits of treatment with your doctor or pharmacist. This drug should be used only in carefully selected patients. Many heart drugs like quinidine (antiarrhythmics) are very effective, but they can infrequently cause new serious (possibly fatal) irregular heartbeats.

USES: This medication is used to treat or prevent many types of irregular heartbeats (heart arrhythmias such as atrial fibrillation). Quinidine can greatly improve your ability to perform normal activities by decreasing the number of irregular heartbeats you have. However, it may not stop all your irregular heartbeats completely. It works by blocking abnormal heartbeat signals.

Before and while you are using quinidine, your doctor may prescribe other medications (e.g., "blood thinners"/anticoagulants such as warfarin, beta blockers such as metoprolol) to shrink any blood clots in the heart and to slow your pulse.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

Quinidine may also be used to treat malaria.

HOW TO USE: Before starting this drug, the manufacturer recommends that you take a test dose (usually a smaller amount than your regular dose) to determine whether you are allergic to it. Consult your doctor or pharmacist for details.

Take this medication by mouth with or without food with a full glass of liquid (8 ounces/240 milliliters) as directed by your doctor. This medication is best taken on an empty stomach, but taking it with food may help decrease stomach upset. Do not lie down for 30 minutes after taking this medication.

If you are taking a long-acting (extended-release) form of quinidine called quinidine gluconate, you should swallow it whole. Do not crush or chew the tablets. Doing so can destroy the long action of the drug and may increase side effects. Some long-acting tablets can be broken in half, so ask your pharmacist whether your brand may be broken.

There are different brands and forms of this medication available. Not all have identical effects. Do not change quinidine products without talking to your doctor or pharmacist.

Dosage is based on your medical condition and response to treatment. If you are taking regular-release quinidine for an irregular heartbeat, the manufacturer recommends that you take no more than 4 grams daily.

Eating grapefruit or drinking grapefruit juice may increase the amount of certain medications in your bloodstream, including quinidine. Consult your doctor or pharmacist for more details.

Avoid large changes in your dietary salt intake while being treated with this medication unless your doctor instructs you otherwise. The amount of salt in your diet may affect the amount of quinidine absorbed by your system. Consult your doctor or pharmacist for more details.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day.

Tell your doctor if your condition does not improve or if it worsens.

SIDE EFFECTS: Diarrhea, nausea, vomiting, loss of appetite, stomach pain/cramps, or a burning feeling in throat or chest (e.g., heartburn) may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Seek immediate medical attention if any of these unlikely but serious side effects occur: severe dizziness, fainting, sudden change in heartbeat (faster/slower/more irregular).

Tell your doctor immediately if any of these unlikely but serious side effects occur: vision changes, eye pain, muscle pain, unusual sweating or shakiness (signs of low blood sugar).

Tell your doctor immediately if any of these rare but very serious side effects occur: unexplained fever/signs of infection (e.g., persistent sore throat), easy bruising/bleeding, extreme tiredness, dark urine, persistent nausea/vomiting, yellowing eyes/skin, lupus-like symptoms (joint/muscle pain, chest pain, change in the amount of urine).

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching, swelling, severe dizziness, trouble breathing.

One type of reaction (cinchonism) can occur after even a single dose of this drug. Contact your doctor of pharmacist promptly if you notice symptoms such as ringing in the ears, sudden hearing problems, headache, blurred vision, confusion. Your dosage may need to be adjusted.

Certain long-acting brands of quinidine may appear as a whole tablet in the stool. This is the empty shell left after the medicine has been absorbed by the body. It is harmless.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

Contact your doctor for medical advice about side effects. The following numbers do not provide medical advice, but in the US you may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088. In Canada, you may call Health Canada at 1-866-234-2345.

PRECAUTIONS: Before taking quinidine, tell your doctor or pharmacist if you are allergic to it; or to quinine; or if you have any other allergies.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: certain types of heart disease (e.g., incomplete or complete heart block without an artificial pacemaker, torsades-type irregular heartbeats, QT prolongation in the EKG, severe heart failure, digitalis toxicity), very low blood pressure, history of easy bruising/bleeding (thrombocytopenic purpura) with use of quinine or quinidine, severe muscle weakness (myasthenia gravis).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, a certain blood disorder (G6PD deficiency), asthma, current infection with fever, very slow heartbeat, low blood potassium/magnesium, family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).

This drug may make you dizzy. Use caution while driving, using machinery, or doing any activity that requires alertness. Limit alcoholic beverages.

Before having surgery, tell your doctor that you are using this medication.

Kidney function declines as you grow older. This medication is removed by the kidneys. Therefore, elderly people may be at greater risk for serious side effects (such as dizziness) while using this drug.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

This drug passes into breast milk. Due to the possible risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.

DRUG INTERACTIONS: Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first. See also How to Use section.

This drug should not be used with the following medications because very serious (possibly fatal) interactions may occur: certain HIV protease inhibitors (e.g., ritonavir, nelfinavir, saquinavir), azole antifungals (e.g., itraconazole, ketoconazole, voriconazole), propafenone, cisapride, arbutamine, mefloquine, drugs that may affect the heart rhythm (QTc prolonging drugs such as amiodarone, sparfloxacin, grepafloxacin, disopyramide, dofetilide, ibutilide, halofantrine, pimozide, droperidol, levomethadyl, bepridil).

If you are currently using any of these medications listed above, tell your doctor or pharmacist before starting quinidine.

Other drugs besides quinidine and those listed above that may affect the heart rhythm (QT prolongation in the EKG) include sotalol, ziprasidone, mesoridazine, and thioridazine, among others. Before using quinidine, report all medications you are currently using to your doctor or pharmacist. QT prolongation can infrequently result in serious (rarely fatal) fast/irregular heartbeat and other symptoms (e.g., severe dizziness, fainting) that require immediate medical attention. Ask your doctor or pharmacist for more details and for instructions on how you may reduce the risk of this effect.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially: large amounts of antacids (e.g., sodium bicarbonate), barbiturates (e.g., phenobarbital), carbamazepine, rifamycins (e.g., rifampin, rifabutin), phenytoin, carbonic anhydrase inhibitors (e.g., acetazolamide), aripiprazole, atomoxetine, codeine, hydrocodone, loperamide, medication for high blood pressure (e.g., nifedipine, verapamil, diltiazem), certain macrolide antibiotics (e.g., erythromycin, clarithromycin), quinupristin/dalfopristin, etravirine, amprenavir/fosamprenavir, certain "water pills" (potassium-wasting diuretics such as hydrochlorothiazide, furosemide).

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe dizziness/fainting, hallucinations, seizures.

NOTES: Do not share this medication with others.

Laboratory and/or medical tests (e.g., complete blood count, liver/kidney function tests, quinidine blood levels, EKG) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at room temperature between 59-86 degrees F (15-30 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-800-854-1166 (USA) or 1-800-668-1507 (Canada).

Information last revised July 2008 Copyright(c) 2008 First DataBank, Inc.